Following our participation at the Festival of Biologics in Basel in October 2026, GenLumina is sharing its latest presentation introducing a new family of silver-based payloads for targeted cancer therapies.
Our technology comprises two complementary modalities:
SnB (SilvernanoBullet) – A novel silver-based payload demonstrating dose-dependent cytotoxic activity in preclinical cancer-cell models without requiring light activation.
SnB* (SilvernanoBullet Star) – Our light-enhanced modality designed to improve efficacy and introduce additional spatial control.
Both modalities are being developed for potential conjugation with antibodies and peptides.
We are actively exploring new proof-of-concept collaborations with pharmaceutical companies, antibody and peptide developers, and strategic investors.
Watch our presentation below to discover our technology and preclinical results.